|
US3536809A
(en)
|
1969-02-17 |
1970-10-27 |
Alza Corp |
Medication method
|
|
US3598123A
(en)
|
1969-04-01 |
1971-08-10 |
Alza Corp |
Bandage for administering drugs
|
|
US3845770A
(en)
|
1972-06-05 |
1974-11-05 |
Alza Corp |
Osmatic dispensing device for releasing beneficial agent
|
|
US3916899A
(en)
|
1973-04-25 |
1975-11-04 |
Alza Corp |
Osmotic dispensing device with maximum and minimum sizes for the passageway
|
|
US4008719A
(en)
|
1976-02-02 |
1977-02-22 |
Alza Corporation |
Osmotic system having laminar arrangement for programming delivery of active agent
|
|
US4537776A
(en)
|
1983-06-21 |
1985-08-27 |
The Procter & Gamble Company |
Penetrating topical pharmaceutical compositions containing N-(2-hydroxyethyl) pyrrolidone
|
|
IE58110B1
(en)
|
1984-10-30 |
1993-07-14 |
Elan Corp Plc |
Controlled release powder and process for its preparation
|
|
DE3853740T2
(de)
|
1987-06-10 |
1995-11-09 |
Dana Farber Cancer Inst Inc |
Bifunktionelle Antikörperkonstruktionen und Verfahren zur selektiven Tötung von Zellbeständen.
|
|
US5073543A
(en)
|
1988-07-21 |
1991-12-17 |
G. D. Searle & Co. |
Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
|
|
IT1229203B
(it)
|
1989-03-22 |
1991-07-25 |
Bioresearch Spa |
Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
|
|
US5120548A
(en)
|
1989-11-07 |
1992-06-09 |
Merck & Co., Inc. |
Swelling modulated polymeric drug delivery device
|
|
ES2259800T3
(es)
|
1990-06-11 |
2006-10-16 |
Gilead Sciences, Inc. |
Procedimientos de uso de ligandos de acido nucleico.
|
|
US5580578A
(en)
|
1992-01-27 |
1996-12-03 |
Euro-Celtique, S.A. |
Controlled release formulations coated with aqueous dispersions of acrylic polymers
|
|
DK1621554T4
(da)
|
1992-08-21 |
2012-12-17 |
Univ Bruxelles |
Immunoglobuliner blottet for lette kæder
|
|
US5591767A
(en)
|
1993-01-25 |
1997-01-07 |
Pharmetrix Corporation |
Liquid reservoir transdermal patch for the administration of ketorolac
|
|
SE9400088D0
(sv)
|
1994-01-14 |
1994-01-14 |
Kabi Pharmacia Ab |
Bacterial receptor structures
|
|
IT1270594B
(it)
|
1994-07-07 |
1997-05-07 |
Recordati Chem Pharm |
Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
|
|
DE69532127T2
(de)
|
1994-07-20 |
2004-08-26 |
Genetics Institute, Inc., Cambridge |
Interaktions-fullensysteme zum nachweis von protein-interaktionen
|
|
EP0739981A1
(en)
|
1995-04-25 |
1996-10-30 |
Vrije Universiteit Brussel |
Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
|
|
WO1997010338A1
(en)
|
1995-09-12 |
1997-03-20 |
Chiron Corporation |
Improved interleukin-6 receptor antagonist
|
|
DK0770397T3
(da)
|
1995-10-18 |
2004-08-09 |
Akzo Nobel Nv |
Newcastle disease viruskombinationsvaccine
|
|
US5986059A
(en)
|
1996-06-14 |
1999-11-16 |
Bayer Corporation |
T-cell selective interleukin-4 agonists
|
|
US6653104B2
(en)
|
1996-10-17 |
2003-11-25 |
Immunomedics, Inc. |
Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells
|
|
DE19742706B4
(de)
|
1997-09-26 |
2013-07-25 |
Pieris Proteolab Ag |
Lipocalinmuteine
|
|
AU3596599A
(en)
|
1998-01-26 |
1999-08-09 |
Unilever Plc |
Method for producing antibody fragments
|
|
AUPP221098A0
(en)
|
1998-03-06 |
1998-04-02 |
Diatech Pty Ltd |
V-like domain binding molecules
|
|
AU2001288405B8
(en)
|
1998-04-03 |
2007-06-14 |
The Penn State Research Foundation |
Amino acid substitution mutants of interleukin 13
|
|
HU229888B1
(en)
|
1998-10-16 |
2014-11-28 |
Biogen Idec Ma Inc Cambridge |
Polymer conjugates of interferon betha-1a and uses
|
|
US6818418B1
(en)
|
1998-12-10 |
2004-11-16 |
Compound Therapeutics, Inc. |
Protein scaffolds for antibody mimics and other binding proteins
|
|
DK1144616T4
(da)
|
1999-01-19 |
2009-03-30 |
Unilever Nv |
Fremgangsmåde til fremstilling af antistoffragmenter
|
|
ATE320486T1
(de)
|
1999-05-05 |
2006-04-15 |
Phylogica Ltd |
Isolierung von biologischen modulatoren aus bibiotheken mit biologisch vielfältigen genfragmenten
|
|
US6794144B1
(en)
|
1999-05-26 |
2004-09-21 |
Licentia Ltd. |
Methods and materials for generating SH3 domains with tailored binding properties
|
|
SE0001877D0
(sv)
|
2000-05-22 |
2000-05-22 |
Klaus Mosbach |
Molecular imprinting
|
|
US20030190598A1
(en)
|
2000-05-26 |
2003-10-09 |
Jasmid Tanha |
Single-domain antigen-binding antibody fragments derived from llama antibodies
|
|
EP1332209B1
(en)
|
2000-09-08 |
2009-11-11 |
Universität Zürich |
Collections of repeat proteins comprising repeat modules
|
|
DE10053224A1
(de)
|
2000-10-26 |
2002-05-08 |
Univ Goettingen Georg August |
Verfahren zur Exposition von Peptiden und Polypeptiden auf der Zelloberfläche von Bakterien
|
|
US20040132094A1
(en)
|
2000-12-13 |
2004-07-08 |
Michael Etzerodt |
Combinatorial libraries of proteins having the scaffold structure of c-type lectinlike domains
|
|
GB0110029D0
(en)
|
2001-04-24 |
2001-06-13 |
Grosveld Frank |
Transgenic animal
|
|
AU2002323501C1
(en)
|
2001-08-30 |
2010-04-29 |
Biorexis Technology, Inc |
Modified transferrin fusion proteins
|
|
JP4213586B2
(ja)
|
2001-09-13 |
2009-01-21 |
株式会社抗体研究所 |
ラクダ抗体ライブラリーの作製方法
|
|
JP2005289809A
(ja)
|
2001-10-24 |
2005-10-20 |
Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) |
突然変異重鎖抗体
|
|
IL149820A0
(en)
|
2002-05-23 |
2002-11-10 |
Curetech Ltd |
Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
|
|
AU2003282724B2
(en)
|
2002-10-02 |
2010-03-04 |
Catalyst Biosciences, Inc. |
Methods of generating and screening for proteases with altered specificity
|
|
WO2004041863A2
(en)
|
2002-11-08 |
2004-05-21 |
Ablynx N.V. |
Single domain antibodies directed against interferon- gamma and uses therefor
|
|
GB0228210D0
(en)
|
2002-12-03 |
2003-01-08 |
Babraham Inst |
Single chain antibodies
|
|
MXPA05007151A
(es)
|
2002-12-31 |
2005-09-21 |
Nektar Therapeutics Al Corp |
Polimeros terminados en maleimida hidroliticamente estables.
|
|
DK1587907T3
(da)
|
2003-01-07 |
2011-04-04 |
Dyax Corp |
Kunitz-domænebibliotek
|
|
TW200526780A
(en)
|
2004-01-06 |
2005-08-16 |
Hayashibara Biochem Lab |
TNF antagonists and TNF inhibitors comprising the same as the active ingredient
|
|
US20060008844A1
(en)
|
2004-06-17 |
2006-01-12 |
Avidia Research Institute |
c-Met kinase binding proteins
|
|
DE102004049479A1
(de)
|
2004-10-11 |
2006-04-13 |
Scil Proteins Gmbh |
Proteinkonjugate zur Verwendung in Therapie, Diagnose und Chromatographie
|
|
DK2439273T3
(da)
|
2005-05-09 |
2019-06-03 |
Ono Pharmaceutical Co |
Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
|
|
US8188223B2
(en)
|
2005-05-18 |
2012-05-29 |
Ablynx N.V. |
Serum albumin binding proteins
|
|
US7399869B2
(en)
|
2005-05-19 |
2008-07-15 |
Genentech, Inc. |
Fibroblast activation protein inhibitor compounds and methods
|
|
PT1907424E
(pt)
|
2005-07-01 |
2015-10-09 |
Squibb & Sons Llc |
Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
|
|
PL2578685T3
(pl)
|
2005-08-23 |
2020-01-31 |
The Trustees Of The University Of Pennsylvania |
Rna zawierający zmodyfikowane nukleozydy i sposoby jego zastosowania
|
|
TW200732347A
(en)
|
2005-10-06 |
2007-09-01 |
Trophogen Inc |
VEGF analogs and methods of use
|
|
EP1806365A1
(en)
|
2006-01-05 |
2007-07-11 |
Boehringer Ingelheim International GmbH |
Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
|
|
EP1892248A1
(en)
|
2006-08-21 |
2008-02-27 |
Eidgenössische Technische Hochschule Zürich |
Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase
|
|
AU2007331672A1
(en)
|
2006-12-15 |
2008-06-19 |
Ablynx N.V. |
Amino acid sequences that modulate the interaction between cells of the immune system
|
|
US9023352B2
(en)
|
2007-02-20 |
2015-05-05 |
Tufts University |
Methods, compositions and kits for treating a subject using a recombinant heteromultimeric neutralizing binding protein
|
|
WO2008124086A2
(en)
|
2007-04-05 |
2008-10-16 |
President And Fellows Of Harvard College |
Chimeric activators: quantitatively designed protein therapeutics and uses thereof
|
|
PL2185589T3
(pl)
|
2007-06-01 |
2016-09-30 |
|
Środki wiążące receptor regionu stałego Fc immunoglobuliny
|
|
BR122017025062B8
(pt)
|
2007-06-18 |
2021-07-27 |
Merck Sharp & Dohme |
anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
|
|
CN101412015B
(zh)
|
2007-10-19 |
2011-08-31 |
深圳富泰宏精密工业有限公司 |
夹具及应用该夹具的挂具结构
|
|
ES2386495T3
(es)
|
2007-11-29 |
2012-08-21 |
Molecular Health Gmbh |
siARN específico de EPH-B4 para reducir el crecimiento de células neoplásicas inducidas por EPO durante el tratamiento de anemia en pacientes con cáncer, receptor de eritropoyetina protector de tejido (NEPOR) y métodos de uso
|
|
EP2262837A4
(en)
|
2008-03-12 |
2011-04-06 |
Merck Sharp & Dohme |
PD-1 BINDING PROTEINS
|
|
JP2012500855A
(ja)
|
2008-08-25 |
2012-01-12 |
アンプリミューン、インコーポレーテッド |
Ｐｄ−１アンタゴニストおよび感染性疾患を処置するための方法
|
|
WO2010030671A1
(en)
|
2008-09-09 |
2010-03-18 |
University Of Medicine And Dentistry Of New Jersey |
Type i interferon antagonists
|
|
US8552154B2
(en)
|
2008-09-26 |
2013-10-08 |
Emory University |
Anti-PD-L1 antibodies and uses therefor
|
|
EP3255060A1
(en)
|
2008-12-09 |
2017-12-13 |
F. Hoffmann-La Roche AG |
Anti-pd-l1 antibodies and their use to enhance t-cell function
|
|
JP5844159B2
(ja)
|
2009-02-09 |
2016-01-13 |
ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ |
Ｐｄ−１抗体およびｐｄ−ｌ１抗体ならびにその使用
|
|
CA2776037A1
(en)
|
2009-10-02 |
2011-04-07 |
Ludwig Institute For Cancer Research Ltd |
Anti-fibroblast activation protein antibodies and methods and uses thereof
|
|
PL2504364T3
(pl)
|
2009-11-24 |
2017-12-29 |
Medimmune Limited |
Ukierunkowane środki wiążące przeciwko B7-H1
|
|
WO2011066342A2
(en)
|
2009-11-24 |
2011-06-03 |
Amplimmune, Inc. |
Simultaneous inhibition of pd-l1/pd-l2
|
|
US20110262348A1
(en)
|
2010-03-29 |
2011-10-27 |
Vrije Universiteit Brussel |
Selective targeting of intratumoral cells
|
|
US8907053B2
(en)
|
2010-06-25 |
2014-12-09 |
Aurigene Discovery Technologies Limited |
Immunosuppression modulating compounds
|
|
SG192673A1
(en)
|
2011-02-10 |
2013-09-30 |
Roche Glycart Ag |
Mutant interleukin-2 polypeptides
|
|
JP6072771B2
(ja)
|
2011-04-20 |
2017-02-01 |
メディミューン，エルエルシー |
Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子
|
|
EA201892619A1
(ru)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
|
EP3559049B1
(en)
|
2011-10-28 |
2025-06-11 |
Teva Pharmaceuticals Australia Pty Ltd |
Polypeptide constructs and uses thereof
|
|
ES2694180T3
(es)
|
2012-01-20 |
2018-12-18 |
Vib Vzw |
Citocinas de haz alfa-helicoidal mutantes dirigidas
|
|
HK1203971A1
(en)
|
2012-05-15 |
2015-11-06 |
Bristol-Myers Squibb Company |
Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
|
|
KR20150131208A
(ko)
|
2013-03-13 |
2015-11-24 |
이미지냅 인코포레이티드 |
Cd８에의 항원 결합 구조체들
|
|
EP2992101B1
(en)
|
2013-04-29 |
2018-10-10 |
Agrosavfe N.V. |
Agrochemical compositions comprising antibodies binding to sphingolipids
|
|
KR102322510B1
(ko)
|
2013-07-18 |
2021-11-08 |
브이아이비 브이지더블유 |
수용체 결합친화성이 현격히 감소된 사이토카인을 수반하는 푸소카인
|
|
JP6595988B2
(ja)
|
2013-07-19 |
2019-10-23 |
ヴィブ ブイゼットダブリュー |
ターゲットされる修飾ｔｎｆファミリーメンバー
|
|
SG10202010429YA
(en)
|
2013-07-19 |
2020-11-27 |
Vib Vzw |
Targeting of cytokine antagonists
|
|
BR112016001128A2
(pt)
|
2013-07-19 |
2018-01-23 |
Vib Vzw |
membros da família il-1 modificados direcionados
|
|
PE20170255A1
(es)
|
2014-01-24 |
2017-03-22 |
Dana Farber Cancer Inst Inc |
Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas
|
|
EP3168717A4
(en)
|
2014-07-11 |
2018-03-14 |
Wacom Co., Ltd. |
Position indicator, position detection device, and input control method for position detection device
|
|
KR102476226B1
(ko)
|
2014-08-05 |
2022-12-12 |
아폴로믹스 인코포레이티드 |
항-pd-l1 항체
|
|
AU2015301936B2
(en)
|
2014-08-11 |
2019-03-07 |
Delinia, Inc. |
Modified IL-2 variants that selectively activate regulatory T cells for the treatment of autoimmune diseases
|
|
DK3186283T3
(da)
|
2014-08-29 |
2020-03-02 |
Hoffmann La Roche |
Kombinationsbehandling med tumormålrettede IL-2- immuncytokinervarianter og antistoffer mod humant PD-L1
|
|
EP4245376A3
(en)
|
2014-10-14 |
2023-12-13 |
Novartis AG |
Antibody molecules to pd-l1 and uses thereof
|
|
CA2973040A1
(en)
*
|
2015-01-09 |
2016-07-14 |
Mabimmune Diagnostics Ag |
Novel anti-fibroblast activation protein (fap) antibodies and uses derived thereof
|
|
GB201500463D0
(en)
|
2015-01-12 |
2015-02-25 |
Cresendo Biolog Ltd |
Therapeutic molecules
|
|
GB201500461D0
(en)
|
2015-01-12 |
2015-02-25 |
Cresendo Biolog Ltd |
Therapeutic molecules
|
|
CN107207606A
(zh)
|
2015-02-02 |
2017-09-26 |
乔治.鲍尔 |
结合并抑制过氧化氢酶和/或超氧化物歧化酶的抗原结合构建体即单域vhh片段以及用于肿瘤疗法的含有它们的药物组合物
|
|
US10421806B2
(en)
|
2015-02-04 |
2019-09-24 |
Abcelex Technologies Inc. |
Anti-salmonella antibodies and uses thereof
|
|
WO2017077382A1
(en)
|
2015-11-06 |
2017-05-11 |
Orionis Biosciences Nv |
Bi-functional chimeric proteins and uses thereof
|
|
CN106928363B
(zh)
*
|
2015-12-30 |
2020-09-25 |
广西医科大学 |
一种FAP纳米抗体Nb12
|
|
CN116769054A
(zh)
|
2016-02-05 |
2023-09-19 |
奥里尼斯生物科学私人有限公司 |
双特异性信号传导剂及其用途
|
|
EP3426278B1
(en)
|
2016-03-07 |
2024-01-03 |
Vib Vzw |
Cd20 binding single domain antibodies
|
|
WO2017165464A1
(en)
|
2016-03-21 |
2017-09-28 |
Elstar Therapeutics, Inc. |
Multispecific and multifunctional molecules and uses thereof
|
|
WO2017194783A1
(en)
|
2016-05-13 |
2017-11-16 |
Orionis Biosciences Nv |
Targeted mutant interferon-beta and uses thereof
|
|
EP3455245A2
(en)
|
2016-05-13 |
2019-03-20 |
Orionis Biosciences NV |
Therapeutic targeting of non-cellular structures
|
|
JP2018035137A
(ja)
|
2016-07-13 |
2018-03-08 |
マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ |
新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用
|
|
WO2018077893A1
(en)
|
2016-10-24 |
2018-05-03 |
Orionis Biosciences Nv |
Targeted mutant interferon-gamma and uses thereof
|
|
CN110573172A
(zh)
|
2017-02-06 |
2019-12-13 |
奥里尼斯生物科学有限公司 |
靶向的工程化干扰素及其用途
|
|
KR102642385B1
(ko)
|
2017-02-06 |
2024-03-04 |
오리오니스 바이오사이언시스 엔브이 |
표적화된 키메라 단백질 및 이의 용도
|
|
WO2018146074A1
(en)
|
2017-02-07 |
2018-08-16 |
Vib Vzw |
Immune-cell targeted bispecific chimeric proteins and uses thereof
|
|
CN110719920B
(zh)
*
|
2017-06-14 |
2024-01-30 |
苏州丁孚靶点生物技术有限公司 |
蛋白质异二聚体及其用途
|
|
CN111511763B
(zh)
|
2017-08-09 |
2024-05-31 |
奥里尼斯生物科学有限公司 |
Cd8结合剂
|
|
EP3664829A4
(en)
|
2017-08-09 |
2021-05-05 |
Orionis Biosciences, Inc. |
LIAISON OFFICERS AT PD-1 AND PD-L1
|
|
AU2018313810B2
(en)
|
2017-08-09 |
2025-05-15 |
Orionis Biosciences BV |
Clec9A binding agents and use thereof
|
|
EP3743448A4
(en)
|
2018-01-26 |
2021-11-03 |
Orionis Biosciences, Inc. |
XCR1 BINDING AGENTS AND USES THEREOF
|
|
KR20210005872A
(ko)
|
2018-03-28 |
2021-01-15 |
오리오니스 바이오사이언시즈 인코포레이티드 |
이작용성 단백질 및 이의 작제물
|
|
WO2020033646A1
(en)
|
2018-08-08 |
2020-02-13 |
Orionis Biosciences, Inc. |
SIRP1α TARGETED CHIMERIC PROTEINS AND USES THEREOF
|
|
US12410225B2
(en)
|
2018-11-08 |
2025-09-09 |
Orionis Biosciences, Inc |
Modulation of dendritic cell lineages
|
|
CA3125527A1
(en)
|
2018-12-20 |
2020-06-25 |
Orionis Biosciences, Inc. |
Particle based small molecule-protein complex trap
|
|
US20220177550A1
(en)
|
2019-03-28 |
2022-06-09 |
Orionis Biosciences, Inc. |
Chimeric proteins and chimeric protein complexes directed to fms-like tyrosine kinase 3 (flt3)
|
|
JP7773372B2
(ja)
|
2019-03-28 |
2025-11-19 |
オリオニス バイオサイエンシズ，インコーポレイテッド |
線維芽細胞活性化タンパク質結合物質およびその使用
|
|
WO2020198659A1
(en)
|
2019-03-28 |
2020-10-01 |
Orionis Biosciences, Inc. |
Fms-like tyrosine kinase 3 ligand (flt3l)-based chimeric proteins
|
|
US12351614B2
(en)
|
2019-03-28 |
2025-07-08 |
Orionis Biosciences, Inc. |
CLEC9A-based chimeric protein complexes
|
|
US11440943B2
(en)
|
2019-03-28 |
2022-09-13 |
Orionis Biosciences, Inc. |
Therapeutic interferon alpha 1 proteins
|
|
WO2020257412A1
(en)
|
2019-06-19 |
2020-12-24 |
Orionis Biosciences, Inc. |
Combination therapy with cd13-targeted chimeric proteins or chimeric protein complexes
|